Aagami, Inc., is an Illinois based life sciences consulting firm offering, Strategic Consulting Out/In Licensing support Partnership / Co- development support Funding and Investment Advisory Divestiture/ M&A IP Licensing and Sale Market Entry / Development Strategy In brief, Aagami brings: Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US Extensive ‘C’ level network nurtured for over 21 years Global Deal making skills, honed for decades Partners having combined experience of 250+ years Supplementing bandwidth to save time, effort & cost 110+ Bio Pharma clients globally have put their trust in Aagami (180+ assignments) since last 21+ years.

1. → Realizing Possibilities, Together ←
110+
Clients
180+
Projects
2020 Calamos Court, Suite 200, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
30+
Countries
21+
Years
January 2024

2. Aagami, Inc.
2
Strategic
Consulting
Global Advisory
Market
Intelligence
Specializing in
110+
Clients
180+
Projects
30+
Countries
Pharma
Consumer
Healthcare
Biotech
Medical
Devices

3. Support all stages of
licensing
(Product/IP/Tech)
from Pre-Clinical to
on the Market
Various types of
development
partnering
support
Support in M&A and
Divestment of Assets,
Techs, IP, Companies
etc.
To augment your
bandwidth in
regions you want
support in.
Licensing/
Commercialization
Partnership /
Co-development
M&A/
Divestiture
Market
Entry/Development
Strategy
Your Needs, we Serve
Advisory and BD
support for
Funding and
Venture Capital
needs
Funding /
Investment
3
We provide these services to help you in achieving the following goals

4. Deep Experience of overcoming business and socio-cultural
differences of various countries/regions
Extensive ‘C’ level
network nurtured for
21+ years
Global Deal making
experience of 250+ years
of all Partners combined
Supplementary services of
Market Intelligence and
Business/IP research
Enhancing your
bandwidth for saving
time, effort & cost
Aagami brings,
4
Our partners have lived and worked in US, Japan, India, Germany, Spain, Colombia among others

5. USA International
5
Completed 180+ projects for 110+ clients since 21+ years
Sample list of Clients
Japan
India
Netherland
Australia
Ireland
NFL BioSciences
France
UK
Sweden
Germany
S. Korea
Portugal
China
Belgium
Israel

6. Samples of diverse successes
Co-Development Partnership for
Novel Protein Therapeutic Platform.
2 Deals Done
Raising Investments for development of
therapeutic vaccines. Listing on OTC
Markets using reverse merger, US$ 10mn
deal signed
Technology Licensing of Dermal
Delivery Platform. 4 Deals signed
with 3 companies for 18 geographies
CONFIDENTIAL
Finding customers for Peptides API.
Partnered with 8 Companies
CONFIDENTIAL
6
Equity Investment from Large Pharma.
AU $17M initial deal done (AU$2M
first tranche paid). Total deal value of
AU $50M+
(More Details in Case Studies). In most cases, Deal size is CONFIDENTIAL
Investments Secured for Portable
MRI System
CONFIDENTIAL

7. Client Testimonials
7
Virtues include Aagami’s
attentiveness, network, and
integrity. Excellent and will
recommend to all
Aagami is the bridge that
crosses many gaps. Importantly
it does so openly and honestly.
Pleased by Aagami’s
professional and gracious work.
Delighted to recommend to
others
Other Consultants we worked
with in the US and Canada do
not even stand in Aagami’s
shadow
Founder and CEO of a California based Biopharma
Founder and CEO of a publicly Listed Australian
Technology Development Company
CEO of a Specialty Chemicals company based in Canada CEO of Oregon, US based Biotech

8. Aagami ‘s Proven Partnering Process
8
All these steps require 60 to 80 hours of effort every month depending upon scope
Setup Prospect Finalize
§ Capture important details about
your assets/technologies
§ Work with you to Finalize ‘Elevator
Pitch (EP)/Teaser’ customized to
specific business culture
§ Based on mutually agreed Criteria,
Identify relevant companies and
decision makers from our
relationships, and resources
nurtured over 21+years
§ This Shortlist is used after your
review and approval
§ Broadcast Elevator Pitch/Teaser by
email to identified Relevant
Companies shortlist
§ Follow-up with phone calls and
emails, if necessary
§ Coordinate CDAs with interested
Companies and You
§ Facilitate further information
exchange and due diligence
§ Organize conference calls for
clarifications
§ Organize and manage meetings
for deal finalization
§ Support in making Term Sheets
§ Advise on structuring the
deal (Very important)
§ Support in negotiations
(Most critical)
§ Complete Agreement
Up to 1 month 3 to 5 months 1 to 12+ months

9. 9
Engagement Model - Monthly Commitment Fee + Success Fee
• This ‘brings skin in the
game’ of both parties
• After 6 months you may
choose to continue based
on progress and experience
• Modified Lehman Formula
of reducing %ages (7 to 3)
is also available
• We get our profits only
from Success Bonus
• A team consisting of
Partner, Consultant & BD
Specialist is deployed
• Works with focus on your
success for our bonus
Dedicated
Teamwork
Small Monthly
‘Commitment’
Fee
Success bonus
A small % of deal value
for at least 6 months
We also work on a simple hourly basis with no minimums.

10. Dinesh Jain
• Founder CEO, MBA
• Working since 1984
• Managed several
companies as CEO, VP, etc
• Lived and worked in 4
countries, 3 continents.
Michael Rosen
Dr. Shridhar
Andurkar, Ph D. Nancy Chew
Dr. Aman Ahuja,
M.D., F.P.M., F.R.C.A.
Godwyn Francis
• Scientific Advisor
• Chair and Prof. of
Pharmaceutical sciences
• Midwestern Univ., Chicago
College of Pharmacy
• Working since 1991
Aagami - Core Team
• Partner, MBA
• Since 1974, Managed 3
MNC Pharma, Agritech,
• US, Europe, Latin
America, Japan & Israel
• Regulatory Expert
• Working since 1979
• A serial entrepreneur,
veteran business
leader, biochemist and
Pharmacologist
• Medical, Clinical
• Pain Specialist and
Anaesthetist uses
multidisciplinary
approach
• Practicing since 1998
• Vice President
• 35+ BioPharma clients
• Ex-Accenture, Prudential
plc, TATA, pManifold
• Working since 2000
Dr. Carlos Velez,
Ph D. MBA
• Partner
• Working since 1998
• CMTx , Lacerta, Connexin,
Panion, Ventac , Penwest,
Frankel
10
Cumulative experience
250+ years
Affiliate Partners based
in Europe and Asia too
USA
USA
India
USA
USA
USA
Australia

11. We are Agnostic to drug, device or therapy types, as
our expertise & experience is in BD and deal making
11
vAagami is drug, device or therapy agnostic,
we work on the business side with decision
makers of companies of all sizes in Biologics,
Pharma and Medtech from across the globe.
vWe have served several clients from over 30
countries and are well positioned to execute the
deal for you.

12. 12
Some transactions did not further happen due to change in strategy by client/other reasons beyond Aagami control/Ongoing discussions
Select Term Sheet level successes (Last ~6 years only)
Client # of Term
sheets & Year
Client Country
1 (2023) WI, USA
CDMO 2 (2022) USA
Ingenio Inc.
1 (2022) China
2 (2022, 2021) CA, USA
3 (2021) TX, USA
1 (2021) Sweden
2 (2021) Japan
Client # of Term
sheets & Year
Client Country
1 (signed 2021) France
2 (2020) Japan
2 (2019) Israel
1 (2019) Israel
3 (2018) Canada
2 (2017) Holland
2 (2017) UK

13. 13
1. Licensing available for Japan: Market
ready Denosumab biosimilar to
PROLIA® & XGEVA®. Other Biosimilars are
also available.
2. Seeking Licensing/Co-development:
A phase 2 (USA) stage Tizanidine
patch using proprietary ILTS
technology for management of
spasticity from Japanese client .
For Licensing/Partnering/Co-development:
3. Seeking JV/Acquisition –Smart Drug
preventing Myelodysplastic Syndromes
(MDS) from advancing to full-scale
myelogenous Leukemia. Second Human
Trial of 30 patients ongoing in AU.
4. Seeking Licensing/Co-development:
Midwest US based Pharma’s First-in-
Class Non-Opioid Analgesic for both
chronic and acute Pain Relief.
Few client opportunities we are currently representing (1 of 3)

14. 14
Few client opportunities we are currently representing (2 of 3)
For Acquisition
1. IP/Asset sale: A small molecule NSAID combination for Migraine using 505(b)(2)
2. Mountain View Pharma (MVP) and its PharmaPEG® technology, product
candidates, data, & IP package - for Next-generation biologics and substantial
returns. Available at a very reasonable price.
3. Asset Sale - Smart Drug preventing Myelodysplastic Syndromes (MDS) from
advancing to full-scale myelogenous Leukemia. Second Human Trial Ongoing in
AU.
4. Asset, Data package and IP Sale - NCE Oral small molecule modulator of mutant
RyR2 for the treatment of CPVT-1/ Heart Arrhythmia (Phase 1 ready). Strong
Preclinical Package.

15. 15
Few client opportunities we are currently representing (3 of 3)
Investment Opportunities
1. Seeking US$15 million: Nose to brain
delivery (intra-nasal and bypassing the
blood brain barrier) technology
development company targeting orphan
diseases such as FrontoTemporal
Dementia (FTD), Alzheimer’s disease,
Dementia with Lewy Bodies and
Parkinson's disease.
2. Seeking US$5 million: A single
(monovalent) vaccine for Targeting
Salmonella, ETEC / E. coli, Campylobacter,
Shigella. Fulfills an unmet need for
treating Bacterial Dysentery.
3. Invest in the future with Integrated
Autoimmune Company: Seeking $10
million for Go to market campaign for
first product and key milestones.
4. $40 Million Series C Open: On the market, US
FDA approved novel portable MRI Guided
Treatment, Diagnosis and Screening, for Urology
applications. California based client.
5. Seeking US$5 million: Midwest US based
Pharma with Phase 2 stage First-in-Class Non-
Opioid Analgesic NCE for Pain Relief.

16. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Equity Investment & Merger on Milestone
• Investments/JV/M&A for further development of its
Biotechnologies and commercialization
16
Australia based company developing novel Biotechnologies application in nutraceuticals
• Aagami identified right investors/ partners, and took them to
20 + companies.
• With focused efforts 3 companies had post CDA level
scientific and technical discussions.
• Aagami kept facilitating and persevering, 1 large company
moved to term sheet level discussions.
• Aagami travelled with client CEO to meet Chairman of
Strategic company in March 2020 to finalise the deal
• Supported client through structuring of the deal and
negotiations. Continued to support after the term sheet and
till definitive agreement was completed in March 2021.
• Large Pharma, acquired 12.5% stake in WRS (March 2021)
with a provision to acquire over 50% on agreed milestone.
• Based on the progress, the agreement has been signed for
100% acquisition.
Name of client partner is
CONFIDENTIAL

17. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for First-in-Class Non-Opioid Analgesic NCE
• Investments and/or partnering to further develop
their lead asset CMX-020.
17
Milwaukee based pharmaceutical company focused on novel treatment for pain relief
• Aagami identified right investors/ partners, and took
them to 50 + companies who are operating in Pain /CNS
• Aagami brough 15+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering. several
companies expressed interest to partner sooner or later.
• Finally Aagami found an investor who transferred the
first tranche in May 2023.
• This enabled client to move one step further in their
development timeline.
• Aagami continues to look for further partnerships and
investments for the client.
• Secured first Investment in April 2023
• Enabled client to move to next steps in their
development timeline.
• Further prospecting in Progress. Client is very happy
and satisfied.
N
H
O
N
O
Log P: 5.01
CLogP: 5.101
CHNO••
Exact Mass: 43.01
Mol. Wt.: 43.02
CNO•••
Exact Mass: 42.00
Mol. Wt.: 42.02
C26H44N2O2
Exact Mass: 416.34
Mol. Wt.: 416.64
CMX-020

18. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnerships for Development and Commercialisation of
Novel Class of Protein Drugs
• The client wanted collaborative partners to develop novel
drugs in Oncology and Ophthalmology using their new class
of proteins - Anticalins®.
German Biotech company making differentiated Novel drugs
• Aagami identified right partners, and took them to 7
interested companies
• With focused efforts three companies moved to term sheet
level discussions. Two companies remained for final
negotiations.
• Aagami maintained its spirits and perseverance knowing
Indian ways of working; even when client was ready to give
up as per Western ways.
• Finally co-development partnership happened in next few
months with one company in Oncology and with another
company for ophthalmic therapy.
• Identifying right companies, advice on deal structure,
perseverance & commitment were the key success factors.
• Client signed co-development deals with 2 companies
in Oct and Dec 2013 respectively
• Aagami proved highly influential in negotiations for
finalization of the deals due to deep experience in
business culture nuances of India.
• The deals helped Pieris in their NASDAQ (PIRS) listing
in 2014, and also enabled higher valuation.
18

19. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for development of therapeutic vaccines
• Investments and partnering to further develop its
technologies and pipeline.
19
Louisiana, US based biotechnology company specializing in innovative cancer treatments
• Aagami scanned the global market, identified right investors/
partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies
moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse
merger with a OTC Markets listed company.
• This enabled access to large sums of funds to develop
clinical stage programs.
• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing
pipeline and technologies

20. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Out-licensing of Transdermal Drug Delivery Technology
• To Out-License TPM® Technology and Co-Develop in clinic
products using proprietary Delivery technology and market
such products in India and larger region.
20
TPM® Technology and Products Company from Australia
• Aagami scanned numerous companies and got 10 relevant
companies interested.
• Discussion with 8 companies progressed.
• Took client to India 3 times for term sheet level meetings
and deal signing.
• Facilitated entire evaluation and deal structuring process
• Aagami made sure testing and other protocols were
honoured before deal was made.
• During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.
• 4 Deals done with 3 global companies
– The first deal was for diclofenac topical gel formulation with
TPM. The Indian partner not only launched their own
product but also out licensed to a major western pharma.
Expanded to 16 more geographies worldwide in 2016.
– The second alliance was for use in Skin Whitening and
under eye cream.
– Third deal – The prospect using TPM increased bio
availability as well as stability of a specific antibiotic. Then
sold off that division for $1.6B

21. Offerings in Market Intelligence/Business Research
Competitive
Landscape
Assessments
Analysis of
Portfolio
Opportunities
identification
Price Discovery
Research
Due Diligence
IP and Regulatory
Research
Financial
Modeling, NPV
valuations
New Market Entry
strategy
Market
development
strategy
21
On need basis at fixed one-time cost

22. Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville, IL 60653, USA
+1-630-364-1837
22
CONTACT US
June 05-08
Dinesh Jain
Founder CEO
dinesh@aagami.com
M: +1 630-853-3520
www.aagami.com
January 8–10, 2024
San Francisco, CA
Dinesh Jain
January 8–10, 2024
San Francisco, CA
JP Morgan Healthcare Week